|
|
|
 |
|
Indications
|
Marketed by Ethicon Endo-Surgery, Inc., the MAMMOTOME® Biopsy System has
already been used in more than 3 million minimally invasive breast biopsy
procedures.
MAMMOTOME ® Indications for Use Statement
The MAMMOTOME ® Biopsy System is indicated to provide tissue
samples for diagnostic sampling of breast abnormalities.
The MAMMOTOME ® Biopsy System is intended to provide breast
tissue for histologic examination with partial or complete removal of the
imaged abnormality.
The MAMMOTOME ® Biopsy System is intended to provide breast
tissue for histologic examination with partial removal of a palpable
abnormality.
The extent of a histologic abnormality cannot always be readily determined
from palpation or imaged appearance. Therefore, the extent of removal of the
palpated or imaged evidence of an abnormality does not predict the extent of
removal of a histologic abnormality, e.g., malignancy. When the sampled
abnormality is not histologically benign, it is essential that the tissue
margins be examined for completeness of removal using standard surgical
procedures.
In instances when a patient presents with a palpable abnormality that has been
classified as benign through clinical and/or radiological criteria (e.g.,
fibroadenoma, fibrocystic lesion), the MAMMOTOME ® Biopsy
System may also be used to partially remove such palpable lesions. Whenever
breast tissue is removed, histological evaluation of the tissue is the
standard of care. When the sampled abnormality is not histologically benign,
it is essential that the tissue margins be examined for completeness of
removal using standard surgical procedures.
|
|
|
|
|
|
|
|
|
 |
|
|